Ophir was delighted to be involved as a Community Partner for Andrew Marmara and his team for the Queensland leg of the Signature 2018 Tour de Cure.
Andrew cycled from Mackay to Cairns to raise funds and awareness for cancer research, support and prevention breakthroughs. Having been personally touched by the devastating impacts of cancer on family members, Andrew felt compelled to take action to support the cause with he and his teammates successfully completing the ride this month and raising much needed funds in the process.
The 1,100km journey took in rain forests, sugar cane fields and cheering school children with the Signature Tour de Cure this year raising in excess of $2.5m to help cure cancer (with over $100,000 donated to grassroots cancer support groups within a number of communities visited along the ride).
Ophir was pleased to provide a small contribution to the effort and we congratulate Andrew (seen below in the centre wearing green gloves) alongside the entire Tour de Cure participants on their momentous effort.
For more information on how you can support this great initiative, head to http://www.tourdecure.com.au/
This document is issued by Ophir Asset Management (AFSL 420 082) in relation to the Ophir Opportunities Fund & the Ophir High Conviction Fund (the Funds) and is intended for wholesale investors only. The information provided in this document is general information only and does not constitute investment or other advice. The content of this document does not constitute an offer or solicitation to subscribe for units in the Funds. Ophir Asset Management accepts no liability for any inaccurate, incomplete or omitted information of any kind or any losses caused by using this information. Any investment decision in connection with the Funds should only be made based on the information contained in the Information Memorandum and/or Product Disclosure Statements.
The monthly ‘Ophir Letter to Investors’ provides readers with a comprehensive overview of the performance of each Ophir Fund, our current investment insights and broader portfolio commentary.